The best studied monoclonal antibody (mAb) affected by the TP53 status is rituximab (RTX) an anti-CD20 mAb that improves patient outcome in B-cell malignancies, and it has been confirmed that CD20 is an important target in CLL [8]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.